A. Radtke and J.-F. Cremers contributed equally to this work.
Diagnosing germ cell neoplasia in situ (GCNis) can detect germ cell tumours (GCTs) at the pre-invasive stage. To date, testicular biopsy with the potential of surgical complications is the only way of safely diagnosing GCNis. Recently, microRNAs (miRs) 371-3, and miR 367 were shown to be valuable serum biomarkers of GCTs. We explored the usefulness of these candidate miRs as a marker for GCNis.
27 patients with GCNis and no concomitant GCT were enrolled. All patients underwent measuring serum levels of miR-371a-3p and miR-367-3p before treatment, 11 had repeat measurement after treatment, 2 also had testicular vein blood examinations. Serum levels were measured by quantitative PCR. In addition, four orchiectomy specimens of patients with GCT were examined immunohistochemically and by in situ hybridization (ISH) with a probe specific for miR-371a-3p to look for the presence of this miR in GCNis cells.
The median serum level of miR-371a-3p was significantly higher in patients with GCNis than in controls, miR-367 levels were not elevated. Overall, 14 patients (51.9%) had elevated serum levels of miR-371a-3p. The highest levels were found in patients with bilateral GCNis. Levels in testicular vein serum were elevated in both of the cases. After treatment, all elevated levels dropped to normal. In two orchiectomy specimens, miR-371a-3p was detected by ISH in GCNis cells.
Measuring miR-371a-3p serum levels can replace control biopsies after treatment of GCNis. In addition, the test can guide clinical decision making regarding the need of testicular biopsy in cases suspicious of GCNis.
Almstrup K, Lippert M, Mogensen HO, Nielsen JE, Hansen JD, Daugaard G, Jörgensen N, Foged N, Skakkebaek N, Rajpert-De Meyts E (2011) Screening of subfertile men for testicular carcinoma in situ by an automated image analysis-based cytologigal test of the ejaculate. Int J Androl 34(4 pt 2):e21–e31 CrossRefPubMed
Berney DM, Algaba F, Amin M, Delahunt B, Compérat E, Epstein JI, Humphrey P, Idrees M, Lopez-Beltran A, Magi-Galluzzi C, Mikuz G, Montironi R, Oliva E, Srigley J, Reuter VE, Trpkov K, Ulbright TM, Varma M, Verrill C, Young RH, Zhou M, Egevad L (2015) Handling and reporting of orchidectomy specimens with testicular cancer: areas of consensus and variation among 25 experts and 225 European pathologists. Histopathology 67:313–324 CrossRefPubMedPubMedCentral
Dieckmann KP, Spiekermann M, Balks T, Ikogho R, Anheuser P, Wosniok W, Loening T, Bullerdiek J, Belge G (2016) MicroRNA miR-371a-3p—a novel serum biomarker of testicular germ cell tumors: evidence for specificity from measurements in testicular vein blood and in neoplastic hydrocele fluid. Urol Int 97(1):76–83 CrossRefPubMed
Murray MJ, Huddart RA, Coleman N (2016) The present and future of serum diagnostic tests for testicular germ cell tumours. Nat Rev Urol 3(12):715–725 CrossRef
Palmer RD, Murray MJ, Saini HK, van Dongen S, Abreu-Goodger C, Muralidhar B, Pett MR, Thornton CM, Nicholson JC, Enright AJ, Coleman N, Cs C a L Group (2010) Malignant germ cell tumors display common microRNA profiles resulting in global changes in expression of messenger RNA targets. Cancer Res 70(7):2911–2923 CrossRefPubMedPubMedCentral
Pelloni M, Coltrinari G, Paoli D, Pallotti F, Lombardo F, Lenzi A, Gandini L (2016) Differential expression of miRNAs in the seminal plasma and serum of testicular cancer patients. Endocrine. doi: 10.1007/s12020-016-1150-z
Rorth M, Rajpert-De Meyts E, Andersson L, Dieckmann KP, Fossa SD, Grigor KM, Hendry WF, Herr HW, Looijenga LHJ, Oosterhuis JW, Skakkebaek NE (2000) Carcinoma in situ in the testis. Scand J Urol Nephrol Suppl 205:166–186 CrossRef
Voorhoeve PM, le Sage C, Schrier M, Gillis AJ, Stoop H, Nagel R, Liu YP, van Duijse J, Drost J, Griekspoor A, Zlotorynski E, Yabuta N, De Vita G, Nojima H, Looijenga LH, Agami R (2006) A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell 124(6):1169–1181 CrossRefPubMed
- Can germ cell neoplasia in situ be diagnosed by measuring serum levels of microRNA371a-3p?
S. A. Mohamed
- Springer Berlin Heidelberg
Neu im Fachgebiet Onkologie
Mail Icon II